Table 5 Estimated direct medical cost savings from the program using the Gilmer approach
A1c change from baseline in Type 2 diabetes patients at 12 months |  |  | ||||
|---|---|---|---|---|---|---|
Baseline A1c levels | A1c < 7% | 7% ≤ A1c < 8% | 8% ≤ A1c < 9% | 9% ≤ A1c < 10% | A1c ≥ 10% |  |
No. of Type 2 diabetes participants with 12-mo follow-up | 133 | 78 | 47 | 27 | 53 | Â |
Average A1c change at 12-month follow-up (std. dev.) | 0.15(±0.73) | −0.24(±0.90) | −0.45(±1.68) | −1.37(±1.55) | −2.9(±2.56) |  |
Number of A1c decreasers | 58 | 50 | 32 | 22 | 45 | Â |
Number of A1c increasers | 64 | 24 | 14 | 5 | 8 | Â |
Number with no A1c change | 11 | 4 | 1 | 0 | 0 | Â |
Cost savings for 1% reduction | −514 | 373 | 1303 | 1374 | 1374 |  |
Average cost savings per person by initial A1c level | −58 | − 220 | −130 | 1057 | 3406 |  |
Program participants initial A1c distribution | 28.9% | 20.5% | 14.9% | 11.6% | 24.0% | Â |
| Â | 2002 USD | 2018 USD | ||||
average cost savings per person (weighted) program saving in 3 years based on 12 m follow-up Estimated current program total cost saving in 3 years | $859 | $1501 | ||||
$178,073 | $311,299 | |||||
$3,314,186 | $5,793,715 | |||||